Literature DB >> 16412769

Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response.

Giuseppe De Placido1, Antonio Mollo, Roberto Clarizia, Ida Strina, Salvatore Conforti, Carlo Alviggi.   

Abstract

Various studies have compared the efficacy of GnRH agonists (GnRH-a) and antagonists (GnRH-ant) for controlled ovarian stimulation (COS) in women undergoing IVF. Nevertheless, few data are available about the use of GnRH-ant in poor responders. Here, a flexible protocol providing a gradual increase in the dose of GnRH-ant in association with recombinant LH (rec-LH) administration is compared with the standard GnRH-a flare-up protocol in 133 women at risk for poor ovarian response. The mean number of metaphase 2 oocytes (primary end point) was significantly higher in the antagonist group (5.73 +/- 3.57 vs. 4.64 +/- 2.23, respectively; P<.05).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16412769     DOI: 10.1016/j.fertnstert.2005.07.1280

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  11 in total

Review 1.  Ovarian stimulation protocols for poor ovarian responders: a network meta-analysis of randomized controlled trials.

Authors:  Man Di; Xiaohong Wang; Jing Wu; Hongya Yang
Journal:  Arch Gynecol Obstet       Date:  2022-06-11       Impact factor: 2.344

Review 2.  Lutropin alfa.

Authors:  Sohita Dhillon; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 3.  Different ovarian stimulation protocols for women with diminished ovarian reserve.

Authors:  D Loutradis; P Drakakis; E Vomvolaki; A Antsaklis
Journal:  J Assist Reprod Genet       Date:  2007-11-22       Impact factor: 3.412

4.  GnRH antagonist multiple dose protocol with oral contraceptive pill pretreatment in poor responders undergoing IVF/ICSI.

Authors:  Chung-Hoon Kim; Rae-Mi You; Hyuk-Jae Kang; Jun-Woo Ahn; Ilkyung Jeon; Ji-Won Lee; Sung-Hoon Kim; Hee-Dong Chae; Byung-Moon Kang
Journal:  Clin Exp Reprod Med       Date:  2011-12-31

5.  Recombinant LH supplementation during IVF cycles with a GnRH-antagonist in estimated poor responders: A cross-matched pilot investigation of the optimal daily dose and timing.

Authors:  Salvatore Gizzo; Alessandra Andrisani; Marco Noventa; Serena Manfè; Alessandra Oliva; Michele Gangemi; Giovanni Battista Nardelli; Guido Ambrosini
Journal:  Mol Med Rep       Date:  2015-06-09       Impact factor: 2.952

6.  A prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF.

Authors:  S Gordts; C Van Turnhout; R Campo; P Puttemans; M Valkenburg; S Gordts
Journal:  Facts Views Vis Obgyn       Date:  2012

7.  Comparison of long GnRH agonist versus GnRH antagonist protocol in poor responders.

Authors:  Sadık Şahin; Selçuk Selçuk; Belgin Devranoğlu; Tayfun Kutlu; Melda Kuyucu; Mustafa Eroğlu
Journal:  Turk J Obstet Gynecol       Date:  2014-12-15

Review 8.  Biological versus chronological ovarian age: implications for assisted reproductive technology.

Authors:  Carlo Alviggi; Peter Humaidan; Colin M Howles; Donald Tredway; Stephen G Hillier
Journal:  Reprod Biol Endocrinol       Date:  2009-09-22       Impact factor: 5.211

9.  A three-arm randomised controlled trial comparing Gonadotrophin Releasing Hormone (GnRH) agonist long regimen versus GnRH agonist short regimen versus GnRH antagonist regimen in women with a history of poor ovarian response undergoing in vitro fertilisation (IVF) treatment: Poor responders intervention trial (PRINT).

Authors:  Sesh K Sunkara; Arri Coomarasamy; Yakoub Khalaf; Peter Braude
Journal:  Reprod Health       Date:  2007-12-28       Impact factor: 3.223

Review 10.  Effective treatment protocol for poor ovarian response: A systematic review and meta-analysis.

Authors:  Yadava Bapurao Jeve; Harish Malappa Bhandari
Journal:  J Hum Reprod Sci       Date:  2016 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.